VPC
MPLT

Vestal Point Capital’s MapLight Therapeutics MPLT Stock Holding History

Vestal Point Capital’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.54M Buy
420,000
+35,000
+9% +$626K 0.24% 67
2025
Q4 		$6.76M Buy
+385,000
New +$6.45M 0.23% 57

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Vestal Point Capital's MPLT Position: Q1 2026 in Review

Vestal Point Capital increased its MapLight Therapeutics (MPLT) stake by 9.1% in Q1 2026, buying an estimated $626K and bringing the position to 420,000 shares worth $8.54M. The position accounts for 0.24% of the portfolio, ranked #67.

Vestal Point Capital first reported a position in MPLT in Q4 2025 and has held it in 2 quarters since. 81 funds tracked by Wall St. Rank hold MPLT as of Q1 2026.

  • Vestal Point Capital held 420,000 shares of MapLight Therapeutics worth $8.54M as of Q1 2026.
  • Vestal Point Capital bought 35,000 MapLight Therapeutics shares in Q1 2026, an estimated $626K.
  • MapLight Therapeutics made up 0.24% of Vestal Point Capital's portfolio in Q1 2026, its #67 holding.
  • Vestal Point Capital first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 81 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q1 2026.

Based on Vestal Point Capital's 13F filing for Q1 2026, filed 15 May 2026.